Efficacy of the Oral mTORC1 Inhibitor Everolimus in Relapsed or Refractory Indolent Lymphoma

American Journal of Hematology - United States
doi 10.1002/ajh.24671
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Evita: Phase I/Ii Study of Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

the mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence

Cancer Discovery
Oncology
2012English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy